Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + minocycline
- Development stage
- Phase 3
- Lead developer
- Bayer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Aspirin + minocycline is a combination of two small molecule drugs—aspirin, an anti-inflammatory and antiplatelet agent, and minocycline, a tetracycline-class antibiotic with additional neuroprotective and anti-inflammatory properties. This combination has been investigated in preclinical models for its potential to enhance cerebroprotection by targeting matrix metalloproteinase (MMP-2 and MMP-9) activity in cerebral ischemia. It has also been studied as adjunctive therapy in bipolar depression due to their combined anti-inflammatory effects. Aspirin acts primarily through irreversible inhibition of cyclooxygenase enzymes (COX-1/COX-2), reducing prostaglandin synthesis; minocycline inhibits bacterial protein synthesis by binding the 30S ribosomal subunit but also exhibits neuroprotective actions via inhibition of microglial activation and MMPs[2][6][7].
- Other names
- aspirin and minocyclineacetylsalicylic acid + minocycline
02
Targets
Bacterial RibosomePGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on aspirin + minocycline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + minocycline.